West Des Moines, Iowa-based Hy-Vee Inc. has announced that COVID-19 antivirals, Molnupiravir and Paxlovid, are available at Hy-Vee pharmacy locations throughout its eight-state region to help treat eligible patients who have mild-to-moderate cases.
The type of COVID-19 antiviral available varies by pharmacy location.
In order to receive a COVID-19 antiviral, patients must have a prescription from their health care provider. The antivirals are free with most insurances.
According to the FDA’s Emergency Use Authorization, Molnupiravir and Paxlovid should be used to treat mild-to-moderate cases in certain adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Paxlovid may also be used to treat mild-to-moderate cases in eligible pediatric patients ages 12+. It is recommended that patients begin COVID-19 antiviral treatment as soon as possible and treatment must begin within five days of when symptoms begin.
Both antiviral products may only be used for the treatment of mild-to-moderate COVID-19 in individuals:
- With positive results of direct COVID-19 viral testing;
- Who are at high risk for progression to severe COVID-19, including hospitalization or death;
- For whom alternative treatment options authorized by FDA are not accessible or clinically appropriate.
Hy-Vee Pharmacy also offers convenient prescription options for patients including drive-thru pharmacy services and free prescription delivery where available.
In addition to COVID-19 antiviral treatments, all Hy-Vee Pharmacy locations also offer over-the-counter, at-home tests. Under the Biden Administration’s ruling, each individual covered under private insurance or Medicare Part B can currently receive up to eight free at-home tests each month.
Hy-Vee Pharmacy also offers other testing options, available by appointment at select locations. Additionally, Hy-Vee Pharmacy offers free vaccines and boosters at all of its pharmacy locations.
To learn more or schedule a vaccination, visit hy-vee.com/covidvaccine.
For more Hy-Vee news from The Shelby Report, click here.
Add Comment